Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. Using microRNA (miRNA) profiling to differentiate noninvasive and ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

Explore surgical options for metastatic bladder cancer, including radical cystectomy and metastasectomy. Learn how surgery can improve survival and quality of life.

Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...

WASHINGTON -- The gene therapy nadofaragene firadenovec (Adstiladrin) continued to demonstrate clinical activity in patients with high-risk bladder cancer, researchers reported. The long-term ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty ...

Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...